medigraphic.com

2016, Número 3

<< Anterior Siguiente >>

Rev Clin Esc Med 2016; 6 (3)


Vacuna contra virus del Papiloma Humano: Análisis de esquemas de dos dosificaciones

Acuña RK, Vega QM, Salazar AN, Escalante GC

Idioma: Español
Referencias bibliográficas: 35
Paginas: 11-22
Archivo PDF: 565.89 Kb.


RESUMEN

La infección por el virus del Papiloma Humano (VPH) es la enfermedad de transmisión sexual más frecuente alrededor del mundo, documentada tanto en mujeres como en hombres. Debido a su papel etiológico en el desarrollo de lesiones premalignas y malignas en diversos sitios anatómicos, se han desarrollado vacunas como herramientas en prevención primaria de estas neoplasias y principalmente en el cáncer de cérvix. Las vacunas aprobadas han demostrado ser altamente efectivas en evitar la transmisión del VPH y el desarrollo de enfermedades relacionadas con su infección, al ser utilizados en esquemas convencionales de tres dosis. Sin embargo, su alto costo y la falta de consistencia en sistemas de dosificación son el principal obstáculo para el éxito. Es por esta razón, que en la actualidad se han realizado numerosos estudios basados en esquemas de dosificación reducidos y sencillos, en los que se compara su efectividad en relación los esquemas usuales, con el objetivo de facilitar la accesibilidad de la vacuna a la población más vulnerable.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Munro A, Cruickshank M. Impact of HPV immunization on the detection of cervical disease. Expert Rev. Vaccines 2014;13:533–544.

  2. Buchanan T, Graybill W, Young J. Morbidity and Mortality of Vulvar and Vaginal Cancers: Impact of 2, 4-, and 9-valent HPV Vaccines. Human Vaccines & Immunotherapeutics 2016; Feb 22:0. [Publi-cación para impresión].

  3. Barr E, Sings H. Prophylactic HPV vaccines: New interventions for cancer control. Vaccine 2008;26: 6244–6257.

  4. Palefsky J, Giuliano A, Goldstone S, et al. HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia. N Engl J Med 2011;365: 1576-1585.

  5. Palefsky, J. Can HPV vaccination help to prevent anal cancer? The Lancet 2010;10:815-816.

  6. Luckett R, Feldman S. Impact of 2-, 4- and 9- valent HPV vaccines on morbidity and mortality from cervical cancer. Human Vaccines & Immunotherapeutics 2015; Nov 20:0. [Publicación para impresión].

  7. Committee on Adolescent Health Care Inmunization Expert Work Group. Human Papillomavirus Vaccination. ACOG 2015;641:1-6.

  8. Bayas J, Costas L, Muñoz A, Cervical cancer vaccination indications, efficacy, and side effects. Ginecologic Oncology 2008;110:11-14.

  9. Giuliano A, Palefsky J, Goldstone S. Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. N Engl J Med 2011;364:401-411.

  10. Toh Z, Licciardi P, Fong J, et al. Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art. Vaccine 2015;33:5042-50.

  11. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof of principle evaluation of the efficacy of fewer than three doses of a biva-lent HPV16/18 vaccine. J Natl Cancer Inst 2011;10:1444–51.

  12. Villa L, Ault K, Giuliano A, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006;24:5571–5583.

  13. Rivera R, Delgado J, Painel V, et al. Mecanismo de infección y transformación neoplásica producido por virus papiloma humano en el epitelio cervical. Rev Chil Obstet Ginecol 2006;71:135-140.

  14. Stanley M. Immune responses to human papillomavirus. Vaccine 2006;24S1:16-22.

  15. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecologic Oncology 2008;109:15-21.

  16. Gattoc L, Nair N, Ault K. Human Papillomavirus Vaccination: Current Indications and Future Directions. Obstet Gynecol Clin N Am 2013;40:177-197.

  17. Stanley M, Gitssmann L, Nardelli-Haefliger D. Immunobiology of Human Papillomavirus Infection and Vaccination-Implications for Second Generation Vaccines. Vaccine 2008;26:62-67.

  18. Ault K. Long-term efficacy of human papillomavirus vaccination. Gynecologic Oncology 2007;107:27-30.

  19. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7:1374-1386.

  20. Safaeian M., Porras C., Yuanji Pan, et al. Durable Antibody Responses Following One Dose of theBivalent Human Papillomavirus L1 Virus-Like ParticleVaccine in the Costa Rica Vaccine Trial. Cancer Prev Res 2013;6:1242-1250.

  21. Kreimer A., Struy F., Raymundo, M. et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. The Lancet Oncol 2015; 16: 775–86.

  22. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309:1793-1802.

  23. Jit M, Choi YH, Laprise JF, et al. Two-dose strategies for human papillomavirus vaccination: How well do they need to protect?. Vaccine 2014;32: 3237–3242.

  24. Kahn J, Bernstein D. HPV Vaccination Too Soon for 2 Doses?. JAMA 2013;309:1832-1833.

  25. Marais D, Passmore JA, Maclean J, et al. A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles. J GenVirol 1999;80:2471–5.

  26. Siegrist CA. Vaccine immunology. In: Plotkin WAO SA, Offit PA, editors. Vaccines. 5th ed. New York, USA: Elsevier; 2008. p. 17–36.

  27. Smolen K, Gelinas L, Franzen L, et al. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012;30:3572-3579.

  28. Kavanagh K, Pollock KG, Potts A, et al. Introductionand sustained high coverage of the HPV bivalent vaccine leads to a reduc-tion in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014;110:2804–11.

  29. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case–control study nested within a population based screening programme in Australia. BMJ 2014;348:1458.

  30. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: adata linkage study. BMC Med 2013;11:227.

  31. Blomberg M, Dehlendorff C, Munk C, Kjaer SK. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nation wide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013;57: 929–34.

  32. Herweijer E, Leval A, Ploner A, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA 2014;311:597–603.

  33. World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014; 89:465–92 (http://www.who.int/wer/2014/wer8943.pdf).

  34. Aljunid S, Maimaiti N, Nur1 A, et al. Cost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia. BMC Public Health 2016;16:1-5.

  35. Laprise JF, Drolet M, Boiy MC, et al. Comparing the cost-effectiveness of two and three dose schedules of human papilloma virus vaccination: A transmission-dynamic modelling study. Vaccine 2014;32:5845-5853.




2020     |     www.medigraphic.com